{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:59:20Z","timestamp":1792799960052,"version":"4.5.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L023032\/1"],"award-info":[{"award-number":["MR\/L023032\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuropharm.2018.01.017","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T03:23:06Z","timestamp":1515727386000},"page":"72-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"special_numbering":"C","title":["Ketamine for the treatment of addiction: Evidence and potential mechanisms"],"prefix":"10.1016","volume":"142","author":[{"given":"I.","family":"Ivan Ezquerra-Romano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Krupitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8858-4906","authenticated-orcid":false,"given":"C.J.A.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.01.017_bib1","doi-asserted-by":"crossref","first-page":"R746","DOI":"10.1016\/j.cub.2013.06.046","article-title":"Memory reconsolidation","volume":"23","author":"Alberini","year":"2013","journal-title":"Curr. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/0269881107078491","article-title":"Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor","volume":"21","author":"Angelucci","year":"2007","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib5","author":"Ballard"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib6","series-title":"Mexican Therapy: \u201cLike the End of the world.\u201d","author":"Barney","year":"1977"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Soc. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2174\/138945009788982496","article-title":"Clinical uses of low-dose ketamine in patients undergoing surgery","volume":"10","author":"Berti","year":"2009","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/ALN.0000000000001275","article-title":"Resting-state network-specific breakdown of functional connectivity during ketamine alteration of consciousness in volunteers","author":"Bonhomme","year":"2016","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/mol.51.4.583","article-title":"Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors","volume":"51","author":"Cai","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib12","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/bja\/aen023","article-title":"Ketamine gargle for attenuating postoperative sore throat","volume":"100","author":"Canbay","year":"2008","journal-title":"Br. J. Anaesth."},{"issue":"20","key":"10.1016\/j.neuropharm.2018.01.017_bib13","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib14","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"201518377","key":"10.1016\/j.neuropharm.2018.01.017_bib15","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/bja\/aeq041","article-title":"Adding ketamine to morphine for intravenous patient-controlled analgesia for acute postoperative pain: a qualitative review of randomized trials","volume":"104","author":"Carstensen","year":"2010","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2012.12.005","article-title":"Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders","volume":"130","author":"Chambers","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3138\/ptc.2009-49P","article-title":"Strategies aimed at preventing chronic post-surgical pain: comprehensive perioperative pain management after total joint replacement surgery","volume":"63","author":"Clarke","year":"2011","journal-title":"Physiother. Can."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jps.2600710516","article-title":"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans","volume":"71","author":"Clements","year":"1982","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2044.1972.tb08186.x","article-title":"Ketamine and the conscious mind","volume":"27","author":"Collier","year":"1972","journal-title":"Anaesthesia"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.drugalcdep.2010.01.012","article-title":"Attentional bias, inhibitory control and acute stress in current and former opiate addicts","volume":"109","author":"Constantinou","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065088","article-title":"Ketamine effects on memory reconsolidation favor a learning model of delusions","volume":"8","author":"Corlett","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib23","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.euroneuro.2012.08.016","article-title":"Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence","volume":"23","author":"Corominas-Roso","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn.2016.28","article-title":"Keep off the grass? Cannabis, cognition and addiction","volume":"17","author":"Curran","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.drugalcdep.2013.12.019","article-title":"Therapeutic infusions of ketamine: do the psychoactive effects matter?","volume":"136","author":"Dakwar","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib26","first-page":"1","article-title":"Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial","author":"Dakwar","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.biopsych.2013.08.009","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","volume":"76","author":"Dakwar","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neubiorev.2012.11.018","article-title":"The effects of N-methyl d-aspartate and B-adrenergic receptor antagonists on the reconsolidation of reward memory: a meta-analysis","volume":"37","author":"Das","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib29","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s00213-015-3990-2","article-title":"Assessing the translational feasibility of pharmacological drug memory reconsolidation blockade with memantine in quitting smokers","volume":"232","author":"Das","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib30","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J.\u00a0Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cpt196563279","article-title":"Pharmacologic effects of CI-581, a new dissociative anesthetic, in man","volume":"6","author":"Domino","year":"1965","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/mp.2012.194","article-title":"Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans","volume":"18","author":"Driesen","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","article-title":"Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder","volume":"16","author":"Duncan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1467-2995.2007.00391.x","article-title":"Clinical evaluation of ketamine and lidocaine intravenous infusions to reduce isoflurane requirements in horses under general anaesthesia","volume":"35","author":"Enderle","year":"2008","journal-title":"Vet. Anaesth. Analg."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib38","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.cell.2014.01.044","article-title":"Neurogenesis in the striatum of the adult human brain","volume":"156","author":"Ernst","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib39","first-page":"1","article-title":"Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine","author":"Fattore","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Garcia-Romeu","year":"2014","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0973-1075.105684","article-title":"Evidence based practice of chronic pain","volume":"18","author":"Garg","year":"2012","journal-title":"Indian J. Palliat. Care"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib42","series-title":"Memory Mechanisms in Health and Disease: Mechanistic Basis of Memory","author":"Giese","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neuroscience.2010.03.032","article-title":"Ketamine impairs recognition memory consolidation and prevents learning-induced increase in hippocampal brain-derived neurotrophic factor levels","volume":"167","author":"Goulart","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib44","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/add.12899","article-title":"Global statistics on addictive behaviours: 2014 status report","volume":"110","author":"Gowing","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib45","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions","volume":"61","author":"Grant","year":"2004","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archpsyc.55.3.259","article-title":"The effect of depression on return to drinking: a prospective study","volume":"55","author":"Greenfield","year":"1998","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib49","series-title":"Beyond the Brain: Birth, Death, and Transcendence in Psychotherapy","author":"Grof","year":"1985"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/02791072.1988.10472511","article-title":"The psychotropic effect of ketamine","volume":"20","author":"Hansen","year":"1988","journal-title":"J.\u00a0Psychoact. Drugs"},{"issue":"20120407","key":"10.1016\/j.neuropharm.2018.01.017_bib52","article-title":"\u201cIt's the way that you look at it\u2019\u2013a cognitive neuropsychological account of SSRI action in depression","volume":"368","author":"Harmer","year":"2013","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib53","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archpsyc.62.10.1097","article-title":"Epidemiology of major depressive disorder: results from the national epidemiologic survey on alcoholism and related conditions","volume":"62","author":"Hasin","year":"2005","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib54","series-title":"A\u00a0Program for the Treatment of Alcoholism: LSD, Malvaria and Nicotinic Acid, in the Use of LSD in Psychotherapy and Alcoholism","author":"Hoffer","year":"1967"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12640-016-9615-7","article-title":"Ketamine affects the neurogenesis of the hippocampal dentate gyrus in 7-day-old rats","volume":"30","author":"Huang","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejpain.2009.08.002","article-title":"Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain","volume":"14","author":"Huge","year":"2010","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib57","series-title":"Ketamine: Dreams and Realities","author":"Jansen","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrn2515","article-title":"The glutamate homeostasis hypothesis of addiction","volume":"10","author":"Kalivas","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib61","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","article-title":"The neural basis of addiciton: a pathology of motivation and choice","volume":"162","author":"Kalivas","year":"2005","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.coph.2014.11.005","article-title":"How does ketamine elicit a rapid antidepressant response?","volume":"20","author":"Kavalali","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib63","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopsych.2004.06.010","article-title":"Increased neurogenesis in a rat ketamine model of schizophrenia","volume":"56","author":"Keilhoff","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib64","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.24972\/ijts.2014.33.2.84","article-title":"Ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications","volume":"33","author":"Kolp","year":"2014","journal-title":"Int. J. Transpers. Stud"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1207\/s15473333thp3404_7","article-title":"Ketamine enhanced psychotherapy: preliminary clinical observations on its effectiveness in treating alcoholism","volume":"34","author":"Kolp","year":"2006","journal-title":"Humanist. Psychol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib67","first-page":"403","article-title":"Entheogen-enhanced transpersonal psychotherapy of addictions: focus on clinical applications of ketamine for treating alcoholism","volume":"3","author":"Kolp","year":"2009","journal-title":"Praeger Int. Collect. Addict"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib68","doi-asserted-by":"crossref","DOI":"10.24972\/ijts.2007.26.1.1","article-title":"Ketamine-enhanced psychotherapy: preliminary clinical observations on its effects in treating death anxiety","volume":"26","author":"Kolp","year":"2007","journal-title":"Int J Transpers. Stud"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib70","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib71","first-page":"24","article-title":"Ketamine psychedelic therapy (KPT) of alcoholism and neurosis. Multidiscip. Assoc","volume":"3","author":"Krupitsky","year":"1992","journal-title":"Psychedelic Stud. Newsl."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J.\u00a0Subst. Abuse Treat."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0006-3223(99)00097-9","article-title":"Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions","volume":"47","author":"Krystal","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib76","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s002130051049","article-title":"Interactive effects of subanesthetic ketamine and haloperidol in healthy humans","volume":"145","author":"Krystal","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002130050503","article-title":"Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans","volume":"135","author":"Krystal","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib79","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002130051125","article-title":"Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats","volume":"146","author":"Kubota","year":"1999","journal-title":"Psychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0259-1162.143110","article-title":"Ketamine: current applications in anesthesia, pain, and critical care","volume":"8","author":"Kurdi","year":"2014","journal-title":"Anesth. Essays Res."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib82","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A\u00a0randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib83","author":"Larkin"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tins.2009.05.002","article-title":"Reconsolidation: maintaining memory relevance","volume":"32","author":"Lee","year":"2009","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.neuron.2005.08.007","article-title":"Disrupting reconsolidation of drug memories reduces cocaine-seeking behavior","volume":"47","author":"Lee","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib86","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1523\/JNEUROSCI.0323-06.2006","article-title":"Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation","volume":"26","author":"Lee","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib87","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40265-017-0702-8","article-title":"Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression","volume":"77","author":"Lener","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib88","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu033","article-title":"BDNF release is required for the behavioral actions of ketamine","volume":"18","author":"Lepack","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib89","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1037\/0033-2909.86.5.1054","article-title":"Psychobiology of active and inactive memory","volume":"86","author":"Lewis","year":"1979","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib90","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib91","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib92","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/sleep\/25.6.615","article-title":"Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep","volume":"25","author":"Lydic","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib93","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","article-title":"Ketamine and the next generation of antidepressants with a rapid onset of action","volume":"123","author":"Machado-Vieira","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib94","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib95","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tins.2011.12.005","article-title":"The addicted brain craves new neurons: putative role for adult-born progenitors in promoting recovery","volume":"35","author":"Mandyam","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0893-133X(97)00113-9","article-title":"Neurobiological similarities in depression and drug dependence: a self- medication hypothesis","volume":"18","author":"Markou","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib97","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.1996.03530340025025","article-title":"A\u00a0double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression","volume":"275","author":"Mason","year":"1996","journal-title":"JAMA1"},{"issue":"159","key":"10.1016\/j.neuropharm.2018.01.017_bib98","article-title":"A\u00a0proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial","volume":"18","author":"McAndrew","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib99","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A\u00a0systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib100","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness","volume":"284","author":"Mclellan","year":"2000","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib101","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.neuron.2005.08.006","article-title":"Molecular substrates for retrieval and reconsolidation of cocaine-associated contextual memory","volume":"47","author":"Miller","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib102","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","article-title":"Ketamine use: a review","volume":"107","author":"Morgan","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cobeha.2016.10.009","article-title":"Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use","volume":"13","author":"Morgan","year":"2017","journal-title":"Curr. Opin. Behav. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib105","first-page":"298","article-title":"Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study","volume":"172","author":"Morgan","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib106","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/35021052","article-title":"Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval","volume":"406","author":"Nader","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib107","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/ALN.0b013e31826a0db3","article-title":"Effect of subanesthetic ketamine on intrinsic functional brain connectivity","volume":"117","author":"Niesters","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib108","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1523\/JNEUROSCI.4256-09.2010","article-title":"Reduction of adult hippocampal neurogenesis confers vulnerability in an animal model of cocaine addiction","volume":"30","author":"Noonan","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib109","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2005.06.018","article-title":"Critical assessment of how to study addiction and its treatment: human and non-human animal models","volume":"108","author":"O'Brien","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.burns.2013.08.021","article-title":"A\u00a02 year experience of nurse led conscious sedation in paediatric burns","volume":"40","author":"O'Hara","year":"2014","journal-title":"Burns"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib111","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.nbd.2012.05.022","article-title":"Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression","volume":"57","author":"Ota","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib112","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0022-3565(25)11430-4","article-title":"Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors","volume":"260","author":"Oye","year":"1992","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-005-0177-2","article-title":"The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers","volume":"183","author":"Parwani","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ALN.0000000000000285","article-title":"(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function","volume":"121","author":"Paul","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1467-2995.2008.00402.x","article-title":"Effects of a low dose infusion of racemic and S-ketamine on the nociceptive withdrawal reflex in standing ponies","volume":"35","author":"Peterbauer","year":"2008","journal-title":"Vet. Anaesth. Analg."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib116","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2004.07.016","article-title":"Antidepressant treatment of co-occurring depression and alcohol dependence","volume":"56","author":"Pettinati","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp053113","article-title":"Mood disorders and substance use disorder: a complex comorbidity","volume":"3","author":"Quello","year":"2005","journal-title":"Sci. Pract. Perspect"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib118","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Rebecca","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib119","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths \u2014 United States, 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbr.2013.02.030","article-title":"mTOR activation is required for the anti-alcohol effect of ketamine, but not memantine, in alcohol-preferring rats","author":"Sabino","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0044799","article-title":"Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action","volume":"7","author":"Scheidegger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib122","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1213\/00000539-199610000-00031","article-title":"Ketamine blocks currents through mammalian nicotinic acetylcholine receptor channels by interaction with both the open and the closed state","volume":"83","author":"Scheller","year":"1996","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib123","series-title":"The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society","author":"Sessa","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib124","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.1000446107","article-title":"Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus","volume":"107","author":"Sheline","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2215-0366(17)30102-5","article-title":"Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight","volume":"4","author":"Singh","year":"2017","journal-title":"The Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib126","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A\u00a0double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib127","first-page":"76","article-title":"Ketamine - more mechanisms of action than just NMDA blockade","volume":"4","author":"Sleigh","year":"2014","journal-title":"Trends Anaesth. Crit. Care"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib128","first-page":"109","article-title":"Alterations of BDNF and GDNF serum levels in alcohol-addicted patients during alcohol withdrawal","volume":"30","author":"S\u00f6nmez","year":"2016","journal-title":"Eur. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib129","first-page":"57","article-title":"Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression","volume":"55","author":"Sos","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1467-2987.2001.00060.x","article-title":"Anaesthesia in horses using halothane and intravenous ketamine-guaiphenesin: a clinical study","volume":"29","author":"Spadavecchia","year":"2002","journal-title":"Vet. Anaesth. Analg."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00005053-199503000-00002","article-title":"Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects","volume":"183","author":"Strassman","year":"1995","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib132","first-page":"22","article-title":"Ketamine as an adjuvant in sympathetic blocks for management of central sensitization following peripheral nerve injury","volume":"3","author":"Sunder","year":"2008","journal-title":"J.\u00a0Brachial Plexus Peripher. Nerve Inj."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib133","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib134","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrn2090","article-title":"Molecular mechanisms of memory reconsolidation","volume":"8","author":"Tronson","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib136","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib137","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]-fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib138","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib139","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.neuroscience.2006.02.062","article-title":"Ketamine affects memory consolidation: differential effects in T-maze and passive avoidance paradigms in mice","volume":"140","author":"Wang","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainres.2012.03.029","article-title":"Interactions between NMDA and dopamine receptors: a potential therapeutic target","volume":"1476","author":"Wang","year":"2012","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2018.01.017_bib141","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1300\/J465v25n01_08","article-title":"Predictors of relapse during treatment and treatment completion among marijuana- dependent adolescents in an intensive outpatient substance abuse program","volume":"25","author":"White","year":"2004","journal-title":"Subst. Abuse"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib142","series-title":"WHO Recommends against International Control of Ketamine [WWW Document]","author":"WHO","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib143","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/alcalc\/37.6.609","article-title":"Anxiety as a predictor of relapse in detoxified alcohol-dependent patients","volume":"37","author":"Willinger","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib144","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib145","series-title":"The WSAVA Global Pain Council (GPC)\u2019s Statement on Ketamine [WWW document]","author":"WSAVA","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib146","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1126\/science.1215070","article-title":"A\u00a0memory retrieval-extinction procedure to prevent drug craving and relapse","volume":"336","author":"Xue","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tp.2015.136","article-title":"R\u00a0-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib148","first-page":"1529","article-title":"Alterations of brain-derived neurotrophic factor serum levels in patients with alcohol dependence","volume":"35","author":"Zanardini","year":"2011","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.017_bib150","first-page":"638","article-title":"A\u00a0randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib151","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FBP.0b013e3282fe88a0","article-title":"Effects of scopolamine and ketamine on reconsolidation of morphine conditioned place preference in rats","volume":"19","author":"Zhai","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib152","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(\u2212)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol., Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.01.017_bib153","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2008.01.033","article-title":"Mechanisms and functional implications of adult neurogenesis","volume":"132","author":"Zhao","year":"2008","journal-title":"Cell"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:52:57Z","timestamp":1758437577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":153,"alternative-id":["S0028390818300170"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.017","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine for the treatment of addiction: Evidence and potential mechanisms","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}